Literature DB >> 24650852

Perforation in colorectal stenting: a meta-analysis and a search for risk factors.

Emo E van Halsema1, Jeanin E van Hooft1, Aaron J Small2, Todd H Baron3, Jesús García-Cano4, Jae Hee Cheon5, Moon Sung Lee6, Se Hwan Kwon7, Stéphanie Mucci-Hennekinne8, Paul Fockens1, Marcel G W Dijkgraaf9, Alessandro Repici10.   

Abstract

BACKGROUND: Recent studies suggest that there is a substantial risk of perforation after colorectal stent placement.
OBJECTIVE: To identify risk factors for perforation from colonic stenting.
DESIGN: A meta-analysis of 86 studies published between 2005 and 2011.
SETTING: Multicenter review. PATIENTS: All patients who underwent colorectal stent placement. INTERVENTION: Colorectal stent placement. MAIN OUTCOME MEASUREMENTS: The occurrence of perforation with subgroup analyses for stent design, stricture etiology, stricture dilation, and concomitant chemotherapy, including the use of bevacizumab.
RESULTS: A total of 4086 patients underwent colorectal stent placement; perforation occurred in 207. Meta-analysis revealed an overall perforation rate of 7.4%. Of the 9 most frequently used stent types, the WallFlex, the Comvi, and the Niti-S D-type had a higher perforation rate (>10%). A lower perforation rate (<5%) was found for the Hanarostent and the Niti-S covered stent. Stenting benign strictures was associated with a significantly increased perforation rate of 18.4% compared with 7.5% for malignant strictures. Dilation did not increase the risk of perforation: 8.5% versus 8.5% without dilation. The subgroup of post-stent placement dilation had a significantly increased perforation risk of 20.4%. With a perforation rate of 12.5%, bevacizumab-based therapy was identified as a risk factor for perforation, whereas the risk for chemotherapy without bevacizumab was 7.0% and not increased compared with the group without concomitant therapies during stent therapy (9.0%). LIMITATIONS: Heterogeneity; a considerable proportion of data is unavailable for subgroup analysis.
CONCLUSIONS: The perforation rate of colonic stenting is 7.4%. Stent design, benign etiology, and bevacizumab were identified as risk factors for perforation. Intraprocedural stricture dilation and concomitant chemotherapy were not associated with an increased risk of perforation.
Copyright © 2014 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24650852     DOI: 10.1016/j.gie.2013.11.038

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  31 in total

1.  Stenting in malignant colonic obstruction--is it a real therapeutic option?

Authors:  Nir Horesh; Joseph Yosef Dux; Moshe Nadler; Alon Lang; Oded Zmora; Einat Shacham-Shmueli; Mordechai Gutman; Ron Shapiro
Journal:  Int J Colorectal Dis       Date:  2015-08-28       Impact factor: 2.571

2.  Colonic perforation either during or after stent insertion as a bridge to surgery for malignant colorectal obstruction increases the risk of peritoneal seeding.

Authors:  Su Jin Kim; Hyung Wook Kim; Su Bum Park; Dae Hwan Kang; Cheol Woong Choi; Byeong Jun Song; Joung Boom Hong; Dong Jun Kim; Byung Soo Park; Gyung Mo Son
Journal:  Surg Endosc       Date:  2015-02-13       Impact factor: 4.584

Review 3.  Complications during colonoscopy: prevention, diagnosis, and management.

Authors:  R Manta; F Tremolaterra; A Arezzo; M Verra; G Galloro; L Dioscoridi; F Pugliese; A Zullo; M Mutignani; G Bassotti
Journal:  Tech Coloproctol       Date:  2015-07-11       Impact factor: 3.781

4.  Surgical Management of Iatrogenic Perforation of the Gastrointestinal Tract: 15 Years of Experience in a Single Center.

Authors:  Christoph Holmer; Christoph A Mallmann; Marlis A Musch; Martin E Kreis; Jörn Gröne
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

5.  Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

Authors:  Minkyu Jung; Min-Hee Ryu; Do Youn Oh; Myounghee Kang; Dae Young Zang; In Gyu Hwang; Keun-Wook Lee; Ki Hyang Kim; Byoung Yong Shim; Eun Kee Song; Sun Jin Sym; Hye Sook Han; Young Lee Park; Jin Soo Kim; Hyun Woo Lee; Moon Hee Lee; Dong-Hoe Koo; Hong Suk Song; Namsu Lee; Sung Hyun Yang; Dae Ro Choi; Young Seon Hong; Kyoung Eun Lee; Chi Hoon Maeng; Jin Ho Baek; Samyong Kim; Yeul Hong Kim; Sun Young Rha; Jae Yong Cho; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2018-02-09       Impact factor: 7.370

6.  Deviating colostomy construction versus stent placement as bridge to surgery for malignant left-sided colonic obstruction.

Authors:  Femke J Amelung; Frank Ter Borg; Esther C J Consten; Peter D Siersema; Werner A Draaisma
Journal:  Surg Endosc       Date:  2016-04-12       Impact factor: 4.584

7.  Role of colonic stents in the management of colorectal cancers.

Authors:  Jayesh Sagar
Journal:  World J Gastrointest Endosc       Date:  2016-02-25

8.  Urgent Management of Obstructing Colorectal Cancer: Divert, Stent, or Resect?

Authors:  Songphol Malakorn; Sharon L Stein; Jeffrey H Lee; Y Nancy You
Journal:  J Gastrointest Surg       Date:  2018-10-03       Impact factor: 3.452

9.  Comparison of through-the-scope stent insertion with standard stent insertion for the management of malignant colorectal obstruction: a prospective study.

Authors:  Y Wan; Y-Q Zhu; N-W Chen; Z-G Wang; Y-S Cheng; J Shi
Journal:  Tech Coloproctol       Date:  2016-09-20       Impact factor: 3.781

10.  Successful endoscopic stent placement as a bridge to surgery for colonic obstruction induced by bevacizumab-based chemotherapy.

Authors:  Shinya Kondo; Takayoshi Fujita; Hayao Nakanishi; Yoshie Tsuzuki; Yu Sobajima; Hiroshi Kojima; Tomomi Okada; Hidemi Goto; Masatoshi Sakakibara
Journal:  Clin J Gastroenterol       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.